The life sciences are poised to reshape human health for generations. But the pipeline of who gets to lead that transformation is fracturing along lines of race, gender, and socioeconomic access — and the cost is measured not just in careers lost, but in cures never found.
In any given year, the National Institutes of Health distributes roughly $47 billion in research grants — the single largest engine of biomedical discovery on Earth. That funding determines which laboratories operate, which hypotheses get tested, and ultimately which therapies reach patients. Yet decades of data reveal a persistent, structural imbalance in who receives those dollars. Black principal investigators are funded at roughly 55% the rate of their white counterparts. Latino and Indigenous researchers face similar headwinds. Women in the biomedical sciences, despite earning more than half of all doctoral degrees, remain dramatically underrepresented among R01 grantees and tenured faculty. The result is a funding gap that quietly shapes the future of medicine — and narrows it.
At Legacy Venture Capital, we study this gap not as a policy abstraction but as an investment signal. When brilliant scientists are systematically under-resourced, entire categories of innovation go unfunded. The therapies that never get built, the platforms never commercialized, the diagnostic breakthroughs never translated from bench to bedside — these represent an enormous loss of scientific and economic value. Understanding the funding gap is essential to understanding where the next generation of transformative life sciences companies will come from.
The disparities are neither new nor subtle. A landmark 2011 study published in Science found that Black applicants to the NIH were 13 percentage points less likely to receive R01 funding than white applicants, even after controlling for education, training, publication record, and prior awards. Follow-up analyses over the subsequent decade showed virtually no improvement. By 2024, a National Academies report confirmed that while modest programmatic interventions had been introduced, the core gap persisted across nearly every institute and funding mechanism.
The gender gap compounds the racial one. Women in biomedical research receive smaller initial grants, are less likely to be renewed, and take an average of two years longer to secure their first major independent award. For women of color, these disadvantages stack. A 2023 analysis in Cell found that Black women investigators received just 0.8% of total NIH funding — a figure wildly disproportionate to their representation in the scientific workforce and entirely disconnected from the quality of their published work.
Funding is not merely a resource; it is a signal of institutional legitimacy. When a researcher fails to secure grants despite strong science, the cascading effects are swift. Without funding, there is no lab staff. Without lab staff, there is no data. Without data, there are no publications. Without publications, there is no tenure. The academic incentive structure is unforgiving, and it disproportionately punishes those who start with fewer resources, smaller networks, and less institutional sponsorship.
The scientists we lose are not failing. They are being failed — by systems that reward pedigree over potential and proximity over paradigm shifts.
A 2024 survey by the American Society for Biochemistry and Molecular Biology found that 40% of underrepresented minority postdoctoral researchers were considering leaving academic science entirely, compared to 22% of their non-minority peers. The top three reasons cited were not lack of passion or ability. They were lack of funding, lack of mentorship, and a pervasive sense that the system was not designed for them to succeed. The result is a brain drain of precisely the researchers whose lived experiences and scientific perspectives could unlock novel approaches to the most urgent problems in human health.
Consider what this means in practical terms. Sickle cell disease, which predominantly affects Black and African-descent populations, was chronically underfunded for decades relative to conditions like cystic fibrosis. Alzheimer's research has historically under-enrolled Latino and Black patients in clinical trials despite their elevated risk profiles. Maternal mortality — where Black women in the United States face death rates three to four times higher than white women — has only recently attracted the concentrated research investment it demands. The composition of who does the science shapes what science gets done.
From a venture perspective, the funding gap represents a profound market inefficiency. The life sciences sector is projected to grow at a 12–14% CAGR over the next decade, driven by aging demographics, a mental health crisis, advances in biological monitoring, and a revolution in scientific tools. Yet the talent pipeline feeding that growth is artificially constrained. When entire populations of trained scientists are filtered out of the innovation ecosystem before they can start companies, the deal flow that reaches venture capitalists is narrower, more homogeneous, and less representative of global health needs.
Research consistently demonstrates that diverse teams produce more innovative science. A study published in PNAS found that scientific papers authored by ethnically diverse teams received 9% more citations than those from homogeneous groups. Patents filed by diverse inventor teams are cited more broadly and generate higher commercial value. In drug development, companies founded by women have been shown to achieve FDA approval with 35% less capital than the industry average. The data is unambiguous: diversity is not a concession — it is a competitive advantage.
When we narrow who gets to build, we narrow what gets built. The therapies, platforms, and diagnostics of the future depend on the scientists we choose to fund today.
Yet the venture capital industry itself mirrors many of the same disparities. In 2025, just 2.2% of all VC funding went to companies with Black founders, and only 2.5% to companies with all-female founding teams. In life sciences specifically, diverse founders report longer fundraising timelines, lower initial valuations, and fewer warm introductions to follow-on investors. The academic funding gap and the venture funding gap are not separate phenomena — they are two stages of the same broken pipeline.
The causes of the funding gap are systemic, not individual. They include biased review processes where evaluators unconsciously favor applicants from familiar institutions and networks. They include topic bias, where research on diseases disproportionately affecting minority populations is judged as less commercially significant. They include the compounding disadvantage of fewer mentors, smaller professional networks, and less access to the informal knowledge — the unwritten rules of grant writing, the introductions to program officers — that lubricates the machinery of academic science.
Addressing these root causes requires action at every level of the ecosystem. At the federal level, the NIH has begun experimenting with alternative funding mechanisms, including the Common Fund's New Innovator Award and the BRAIN Initiative's diversity supplements. These programs show promise but remain small relative to the scale of the problem. Institutional reforms — such as blinding grant reviews, diversifying study sections, and providing bridge funding for early-career investigators from underrepresented backgrounds — are gaining traction at leading research universities but are far from universal.
Private capital has a distinct and critical role to play. Unlike government grants, venture investment can move fast, take risks on unconventional founders, and provide the kind of strategic support — operational mentorship, network access, commercial expertise — that translates scientific talent into viable companies. The question is whether the venture industry will choose to look beyond its traditional networks and source from the full depth of the scientific talent pool.
Legacy Venture Capital was founded on the conviction that the best life sciences companies of the next decade will come from founders the traditional ecosystem has overlooked. Our investment thesis — biology that enables human potential — is inseparable from our commitment to expanding who gets to participate in that vision. We invest at pre-seed and seed, the stages where the funding gap is most acute and where a single check can determine whether a scientist stays in the arena or walks away.
The funding gap is not an intractable problem. It is, at its core, a capital allocation failure — and capital allocation failures are exactly what venture capital exists to correct. When we invest in scientists who have been systematically under-resourced, we are not making a charitable bet. We are accessing a mispriced asset class: extraordinary scientific talent that the market has irrationally discounted.
The most transformative companies of the next decade will be built by founders the old system never saw coming. Our job is to find them first.
The molecular systems we study to treat disease are the same systems we can use to expand human capacity. But that expansion cannot happen if we leave half the talent on the sideline. Closing the funding gap is not just a moral imperative — it is the single highest-leverage strategy for accelerating the future of human health. The science is there. The founders are there. The question is whether the capital will follow.
Legacy Venture Capital invests in visionary scientist-founders at the earliest stages. If you're building biology that enables human potential, we want to hear from you.
Resources for Founders